Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

IRX4204

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Early life exposure to endocrine-disrupting chemicals (EDCs) is an emerging risk factor for the development of obesity and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
e14095Background: IRX4204 is a Retinoid X Receptor (RXR) specific agonist (rexinoid). IRX4204 has high potency as a RXR agonist… Expand
Is this relevant?
2017
2017
Obesity is a global pandemic. Nearly 40% of adults and 20% of all children in the United States are classified as obese. There… Expand
Is this relevant?
2016
2016
Retinoid x receptors (RXRs) are master regulators that control cell growth, differentiation, and survival and form heterodimers… Expand
Is this relevant?
2016
2016
Parkinson's disease (PD) is one of the most common movement disorders, and currently there is no effective treatment that can… Expand
Is this relevant?
2016
2016
Objective: To evaluate the safety, tolerability, and effects on dopamine transporter binding (DAT), UPDRS Total and Motor Score… Expand
Is this relevant?
2016
2016
Objective: To facilitate translation of the selective RXR nuclear receptor agonist IRX4204 into clinical trials in MS and other… Expand
Is this relevant?
2014
2014
169 Background: IRX4204 is a potent, selective, oral small compound agonist of retinoid X receptor (RXR) nuclear receptor… Expand
Is this relevant?
2014
2014
Background: Activation of retinoid X receptors (RXR) as homodimers, or as heterodimers with other nuclear receptors, results in… Expand
Is this relevant?
2014
2014
Background: IRX4204 is a potent and highly selective small compound agonist of the RXR nuclear receptors. IRX4204 transactivates… Expand
Is this relevant?